Our medical and scientific team continues research to improve therapies and offer additional treatment options. Contact a BioXcellerator Patient Advocate to see if new treatments are available for your condition.

Schedule Your Free Consultation

Free Consultation

Intervertebral Disc Repair by Autologous Mesenchymal Bone Marrow Cells – A Pilot Study

For many individuals, the burden of chronic back pain is an unwelcome companion—a constant reminder of the limitations imposed by a condition that has long been a challenge for the medical community. Degenerative disc disease, a common cause of such pain, is characterized by the progressive deterioration of the intervertebral discs that provide cushioning between the vertebrae of the spine. As the discs wear down and lose hydration, individuals may experience pain, stiffness, and reduced mobility. Traditional treatment options, such as pain medication, physical therapy, and surgical interventions, often fall short of providing lasting relief, leaving those affected to grapple with the physical and emotional toll of unrelenting discomfort.

Amidst this landscape of adversity, a glimmer of hope emerged. Scientists and medical researchers had been exploring the regenerative potential of stem cells—the body’s own repair agents with the ability to differentiate into various cell types and promote healing. In particular, mesenchymal bone marrow stem cells (MSCs) caught the attention of the scientific community as potential candidates for repairing damaged intervertebral discs. Could this be the solution that patients had been waiting for? Could stem cells hold the key to unlocking the body’s inherent ability to heal and restore itself?

In the quest to answer these questions, a dedicated team of medical professionals and researchers embarked on a groundbreaking clinical trial, Intervertebral Disc Repair by Autologous Mesenchymal Bone Marrow Cells: A Pilot Study. For the first time in history, autologous MSC transplantation—a therapy involving the isolation, expansion, and transplantation of a patient’s own MSCs—would be tested in humans with the goal of repairing damaged intervertebral discs and alleviating chronic back pain. It was a bold and courageous undertaking, fueled by the promise of scientific innovation and the unwavering dedication of the medical team to improve the lives of those affected by degenerative disc disease.

Results of the Trial

It was a day of hope and promise for the ten patients who volunteered for this pioneering clinical trial—one that held the potential to revolutionize the treatment of chronic back pain caused by degenerative disc disease. With each patient’s consent, the medical team embarked on a journey to explore the therapeutic effects of using autologous MSCs to repair damaged intervertebral discs.

The idea of using MSCs to treat degenerative disc disease had been gaining traction in the scientific community, thanks to promising results from in vitro and animal studies. But this was different. This was the first time the therapy was to be tested in humans, and the stakes were high. The trial began with each patient undergoing bone marrow harvesting from their iliac crest. It was a simple procedure performed under local anesthesia with slight sedation. The medical team then isolated and expanded the patients’ MSCs in a controlled laboratory setting, ensuring high-quality standards and safety.

Once the MSCs were ready, the patients returned for the next phase of the trial—transplantation. The medical team skillfully injected the stem cells into the nucleus pulposus area of the affected spinal disc segment. It was a minimally invasive intervention that allowed patients to be discharged after a brief observation period.

As the days and weeks passed, something remarkable happened. The patients began to experience significant relief from their chronic back pain. At the three-month mark, a remarkable 85% of the total improvement in pain was attained. It was a rapid and significant analgesic effect that left the patients feeling hopeful for the future. In total, nine out of the ten patients reported significant improvement in their condition.

As the medical team continued to monitor the patients, they found that the fluid content of the affected disc segments increased significantly by the end of the first year. This meant that the MSCs were helping to stop the progression of disc dehydration—a key factor in degenerative disc disease. Not only were the patients experiencing less pain, but their discs were also showing signs of rejuvenation.

The exact mechanism behind this beneficial effect remained a mystery, but the medical team had some theories. They speculated that the MSCs, once implanted, could be stimulating the production of anti-inflammatory cytokines, reducing inflammation, and helping the nucleus pulposus cells to synthesize extracellular matrix. These actions could contribute to the regeneration of the disc tissue and improvement in overall spinal health.

While the patients were experiencing significant improvements in their quality of life, the journey was not without challenges. The team recognized that this was only the beginning of a long road ahead. Long-term follow-up studies were needed to assess the durability of the treatment’s effects, evaluate potential systemic implications, and address concerns about possible facilitation of systemic infections and tumor growth. The trial served as a pilot phase, a starting point for the future exploration of this innovative therapy on a larger scale.

The success of this trial marked a transformative moment in the field of regenerative medicine. It opened doors to further research and clinical trials with larger cohorts of patients and longer follow-up periods. These studies would seek to track the long-term evolution of pain, disability, disc height, and disc water content in patients, providing valuable insights into the anatomical and functional changes that occur in the intervertebral spaces over time.

The medical team also envisioned exploring the possibility of cryopreserving a portion of the harvested MSCs for subsequent multi-dose applications. This would offer patients the opportunity for future treatments without the need for additional bone marrow harvesting, thereby minimizing the invasiveness of the treatment even further.

As the trial concluded, the patients and the medical team were filled with a sense of accomplishment and gratitude. The patients expressed their deep appreciation for the positive impact the treatment had on their lives—relieving their pain, restoring their mobility, and allowing them to pursue their daily activities with renewed vigor. For the medical team, the trial underscored the immense potential of stem cell therapy as a game-changer in the management of chronic back pain and degenerative disc disease.

Skip to content